Vizsgálati helyszín
Buenos Aires
Buenos Aires, 1431, ArgentínaMég nincs intézményhez kötve
- 14futó vizsgálat
- 2lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 16 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis9 vizsgálat
- 2. fázis6 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz8 vizsgálat
- Toboroz5 vizsgálat
- Lezárult2 vizsgálat
- Meghívásos bevonás1 vizsgálat
Futó vizsgálatok
Toboroz
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931· 3. fázis· Sanofi· Forrás
Toboroz
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222· 3. fázis· Sanofi· Forrás
Toboroz
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209· 3. fázis· Sanofi· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
NCT06812988· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319· 2. fázis· Sanofi· Forrás
Meghívásos bevonás
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· 2/3. fázis· Sanofi· Forrás
Fut, nem toboroz
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166· 3. fázis· Sanofi· Forrás
Toboroz
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
NCT02991469· 2. fázis· Sanofi· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek